Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Sawalha Y, Bond DA, Alinari L. Onco Targets Ther. 2020;13:6573—6581. The authors have advised that there is an error in Table 2 on page 6579. The values “37% (0%)” in the first row for the Ibrutinib column should read “10% (0%)&r...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2020-09-01
|
| Series: | OncoTargets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/corrigendum-evaluating-the-therapeutic-potential-of-zanubrutinib-in-th-peer-reviewed-article-OTT |